Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 3/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318171 | 1.00 | MAPT (0.37) | MAPTALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL989212 | 0.92 | MAPT (0.38) | MAPTALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL989215 | 0.92 | MAPT (0.38) | MAPTALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL988880 | 0.90 | MAPT (0.37) | MAPTALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL988879 | 0.90 | MAPT (0.37) | MAPTALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL13255695 | 0.89 | ABCG2 (0.36) | MAPTALDH1A1HSD17B10ABCG2KDM4E | |
| SCHEMBL2319454 | 0.88 | PARP1 (0.38) | MAPTALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL2319459 | 0.88 | PARP1 (0.38) | MAPTALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL3674775 | 0.87 | KDM4E (0.43) | MAPTALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL3674777 | 0.87 | KDM4E (0.43) | MAPTALDH1A1MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213664-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| EP-1421069-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| EP-2213664-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG International Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-7250511-B2 | Process for the preparation of cyclopenta[g]quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| US-7250511-B2 | Process for the preparation of cyclopenta[g]quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| US-20040266798-A1 | Process for the preparation of cyclopenta[g]quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1421069-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG International Limited (GB) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003020706-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[g]QUINAZOLINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266798-A1 | Process for the preparation of cyclopenta[g]quinazoline derivatives | COX6A1, MT-ND6, CYP2D6 | MAPT 3724/4885ALDH1A1 1243/4885MEN1 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.